News

Keymed Biosciences Announces Breakthrough in Allergy Treatment

Keymed Biosciences Announces Breakthrough in Allergy Treatment

Breakthrough Study of Stapokibart in Seasonal Allergic Rhinitis

Keymed Biosciences Inc. (HKEX: 02162) has released significant results from the Phase III trial of its novel IL-4R? antibody known as stapokibart, aimed at providing relief for individuals suffering from moderate-to-severe seasonal allergic rhinitis (SAR). This landmark study, led by Professor Luo Zhang, highlights the first clinical findings on an IL-4R?-targeted biologic for SAR, reflecting a pivotal advancement in the field of allergic rhinitis treatment.

Effective Relief from Symptoms

The Phase III study clearly demonstrates that stapokibart effectively alleviates clinical symptoms associated with SAR, significantly improving the quality of life for patients who have not found sufficient relief from standard therapy options. This innovative treatment represents a pivotal shift in managing allergic rhinitis, offering hope to the millions affected by this condition worldwide.

Rapid and Effective Nasal Symptom Control

The results indicate that patients treated with stapokibart experienced a rapid alleviation of nasal obstruction symptoms. Notably, by Day 2, those in the treatment group showed significantly greater relief compared to the placebo group. By Day 7, an impressive 72% of patients reported clear nasal breathing, with cumulative rates reaching 86% by Week 2 and 94% by Week 4.

Potency and Continuity of Effect

Stapokibart users noted a significant reduction in the daily reflective total nasal symptom score (rTNSS) as early as Day 4, where scores improved by 2.7 points from baseline, which surpassed the improvements of the placebo group. During the 2-week treatment phase, a remarkable 3.6-point improvement was achieved compared to baseline, and the 4-week analysis indicated a 4.9-point reduction in rTNSS, showcasing substantial progress in patient outcomes.

Marked Improvements in Ocular Symptoms

The study also monitored ocular symptom improvements, demonstrating that stapokibart provided clinically significant reductions in daily reflective Total Ocular Symptom Score (rTOSS). Noteworthy enhancements of 2.6 points at Week 2 and 3.7 points at Week 4 outperformed placebo results, with a majority of patients achieving mild or no ocular symptoms by the conclusion of the study.

Reducing Inflammation at Its Source

Another critical finding of the study was the reduction in type 2 inflammatory biomarkers among those treated with stapokibart, highlighting its dual action against allergic rhinitis. Within the 4-week timeframe, notable declines in total serum IgE and allergen-specific IgE levels were observed, along with reductions in nasal secretion biomarkers like cystatin SN and eotaxin-3.

Safety Profile of Stapokibart

In terms of safety, stapokibart exhibited a favorable profile among study participants, with rates of treatment-emergent adverse events comparable to those experienced by participants receiving placebo. No serious adverse events were reported, contributing to the positive evaluation of stapokibart as a viable treatment option for SAR.

Pioneering Future Research

Conclusively, the PHECDA trial marks a significant leap forward in targeted biologic therapy for seasonal allergic rhinitis. Following these findings, stapokibart received approval from China's National Medical Products Administration (NMPA), establishing it as the world's first IL-4R? monoclonal antibody for SAR. This approval not only presents a new treatment alternative for patients enduring moderate-to-severe refractory SAR but also reinforces the leadership position of clinical scientists in the field of allergic rhinitis research.

Frequently Asked Questions

What is stapokibart?

Stapokibart is an IL-4R? targeted antibody developed by Keymed Biosciences for treating moderate-to-severe seasonal allergic rhinitis.

What were the main findings of the Phase III study?

The Phase III study found that stapokibart significantly improved nasal and ocular symptoms and reduced inflammatory biomarkers in patients with SAR.

How quickly did patients experience relief?

Patients using stapokibart reported significant improvements in nasal obstruction by Day 2, with most achieving optimal results by Week 4.

Was stapokibart safe for patients?

Yes, the study indicated that stapokibart had a favorable safety profile, with adverse events comparable to the placebo group.

When was stapokibart approved?

Stapokibart received approval from China’s National Medical Products Administration (NMPA) as an innovative treatment for SAR.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 65

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 73

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 113

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 62

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading
Ontario Airport Braces for Holiday Travel Surge

Updated Category News Views 92

Gearing Up for a Thanksgiving Travel Boom Think Thanksgiving brings only turkey to the table? Down in Ontario, California, it's all about jet fuel and passenger counts. The Ontario International Airport (ONT) is where the skies are buzzing, forecasting over 227,000 passengers trying to soak up the holiday vibes by air. Compare that to the numbers when the local folks...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 101

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 119

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading

Top 5 Most Recently Viewed Articles

Koin CU and North Star CCU Utilize Mahalo for Digital Banking

Updated Category News Views 151

Revolutionizing Member Experience with Mahalo’s Platform Koin Credit Union and North Star Community Credit Union are excited to announce their partnership with Mahalo Banking, leveraging the innovative Thoughtful Banking platform to enhance the digital banking experience for their members. This collaboration signifies a commitment by both credit unions to prioritize...

Continue Reading
Exploring the Short Interest Trends of Bloom Energy Corp

Updated Category News Views 409

Bloom Energy Corp: Understanding Recent Short Interest Trends Bloom Energy Corp (NYSE: BE) has recently seen its short interest as a percentage of float decrease by 3.47%. According to the latest data, about 39.43 million shares are sold short, equating to approximately 23.93% of the available shares for trading. This situation indicates that traders would require an...

Continue Reading
Hurricane Season 2025: Essential Travel Insurance Insights

Updated Category News Views 315

Hurricane Season 2025: What Travelers Need to Know As hurricane season approaches in 2025, there are increasing concerns about its potential severity. Experts anticipate this could be one of the most active seasons we have seen in years, with predictions suggesting an alarming number of storms. With the aviation sector facing ongoing challenges and emergency training...

Continue Reading
Allendale Social: Nominated for Best Dining Honors

Updated Category News Views 310

Allendale Social Recognized for Culinary Excellence Allendale Social has received nominations for two esteemed categories from 201 Magazine: Best Fine Dining and Best New Restaurant. This recognition highlights the restaurant's commitment to quality and the exceptional dining experience it has cultivated in a relaxed yet upscale environment. The voting process is crucial,...

Continue Reading
Insmed Induces Growth with New Employee Stock Grants

Updated Category News Views 167

Insmed's Strategic Inducement Grants Enhance Workforce Insmed Incorporated (Nasdaq: INSM), a leading global biopharmaceutical company, has recently made headlines by announcing a significant inducement grant aimed at bolstering its workforce. This initiative highlights Insmed's commitment to attracting top talent to support its mission of developing transformative...

Continue Reading